Ide Hiroki, Satou Atsuko, Hoshino Katsura, Yasumizu Yota, Uchida Yasumitsu, Tasaka Yuji, Masuda Takeshi
Department of Urology, Saitama Municipal Hospital, Saitama, Japan. h-ide @ fc4.so-net.ne.jp
Urol Int. 2011;87(2):245-7. doi: 10.1159/000327511. Epub 2011 Jun 28.
This is the first report of urothelial carcinoma (UC) in a hemodialysis (HD) patient treated with almost the same doses of gemcitabine and paclitaxel (GP) as those administered to patients with normal renal function. There have been some reports of UC treated with cisplatin-based chemotherapy in HD patients. However, there have only been a few reports of UC treated with GP in HD patients. Furthermore, to our knowledge, there has not been any report of UC in a HD patient treated with almost the same doses of GP as those in patients with normal renal function. Following cystectomy for bladder cancer, a 73-year-old woman undergoing HD developed lung metastasis and received combination chemotherapy with almost the same doses of GP as those in patients with normal renal function. After three cycles were completed, metastatic tumors disappeared and there has not been any recurrence or metastasis for 1 year to date. Furthermore, there were no grade 3 or 4 adverse effects during this treatment.
这是关于一名血液透析（HD）患者发生尿路上皮癌（UC）的首例报告，该患者接受的吉西他滨和紫杉醇（GP）剂量与肾功能正常患者所使用的剂量几乎相同。此前有一些关于HD患者接受以顺铂为基础的化疗治疗UC的报告。然而，关于HD患者接受GP治疗UC的报告却很少。此外，据我们所知，尚无HD患者接受与肾功能正常患者几乎相同剂量的GP治疗UC的报告。一名73岁接受HD治疗的女性在因膀胱癌行膀胱切除术后发生肺转移，并接受了与肾功能正常患者几乎相同剂量的GP联合化疗。三个周期治疗完成后，转移瘤消失，至今1年未出现复发或转移。此外，该治疗过程中未出现3级或4级不良反应。
